Analysis of activation-induced cytidine deaminase mRNA levels in patients with chronic lymphocytic leukemia with different cytogenetic status


Gelmez M. Y., Teker A. B. A., Aday A. D., Yavuz A., Soysal T., Deniz G., ...Daha Fazla

LEUKEMIA & LYMPHOMA, cilt.55, sa.2, ss.326-330, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 2
  • Basım Tarihi: 2014
  • Doi Numarası: 10.3109/10428194.2013.803225
  • Dergi Adı: LEUKEMIA & LYMPHOMA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.326-330
  • Anahtar Kelimeler: AID, gene expression, CLL, B-CELLS, HIGH EXPRESSION, AID EXPRESSION, GENE, DIAGNOSIS, DISEASE, CLL, HYPERMUTATION, GUIDELINES, REGIONS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Activation induced cytidine deaminase (AID) enzyme, which converts cytosine into uracil and is expressed only by activated B lymphocytes, plays a role in B cells in both the mechanisms of somatic hypermutation (SHM) and class switch recombination (CSR). There are studies showing that AID can cause numerous translocations in different lymphoproliferative diseases. Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of monoclonal B cells in bone marrow and peripheral blood. The predictability and clinical status of B-CLL are difficult to determine. About 30-50% of patients have chromosomal abnormalities. AID, which is thought to create fraction segments for translocations, might also cause deletions in DNA regions of 17p13, 11q22.3, 13q14 and 13q34 that are associated with prognostic implications in patients with CLL. In this study, the AID gene expression in patients with CLL with and without deletions was investigated. When compared to healthy subjects and patients without deletions, increased levels of AID expression in patients with deletions of 17p13, 11q22.3 or 13q14 were found, but not for the 13q34 region. Our results show that AID expression may be associated with deletions in patients with CLL.